Systemic and intrathecal baclofen produce bladder antinociception in rats

BMC Urology

Table 2 Effect of IT baclofen and a GABA_B receptor antagonist on responses to urinary bladder distension in rats with and without previous episode of bladder inflammation as neonates and/or as adults (data presented as % baseline AUC)

Pretreatments	NBI	No NBI	No NBI
Pretreatments	Plus ABI	Plus ABI	No ABI
SEQUENCE 1
Saline IT	145.8 ± 24.0	110.1 ± 5.7	132.1 ± 15.9
Then 40 ng IT baclofen	46.1 ± 10.9*	63.5 ± 12.8*	64.7 ± 17.3*
SEQUENCE 2
CGP35348 IT (30 mcg)	104.1 ± 12.7	101.2 ± 6.0	138.5 ± 25.0
Then 40 ng IT baclofen	90.7 ± 11.3^#	102.1 ± 5.7^#	134.8 ± 28.5^#
SEQUENCE 3
CGP35348 IT (30 mcg)	106.2 ± 13.8	130.7 ± 12.7	123.8 ± 13.5
Then saline IT	112.7 ± 19.7	144.1 ± 12.1	129.4 ± 27.4
SEQUENCE 4
Saline IT	110.8 ± 9.3	111.2 ± 10.2	129.4 ± 16.3
Then Saline IT	88.3 ± 18.2	94.9 ± 9.9	143.3 ± 19.4

Data represents mean ± SEM
CPG35348 is a selective GABA_B receptor antagonist
NBI neonatal bladder inflammation—pretreatment as defined in section “Neonatal bladder inflammation (NBI)” of text; ABI adult bladder inflammation—pretreatment as defined in section “Adult bladder inflammation (ABI)” of text; mcg microgram, ng nanogram
*Statistically significant change (p < 0.05, paired t-test) from previous measure. N = 8–9/group
^#Statistically significant difference from Saline-IT Baclofen treated rats in same Pretreatment category (p < 0.05, unpaired t-test)

ISSN: 1471-2490